nodgoРоссийский журнал детской гематологии и онкологии (РЖДГиО)Russian Journal of Pediatric Hematology and Oncology2311-12672413-5496LTD “Graphica”10.17650/2311-1267-2017-4-2-85-90nodgo-298Research ArticleОригинальные исследованияВысокодозная химиотерапия с трансплантацией аутологичных кроветворных стволовых клеток при лимфоме Ходжкина. Десятилетний опыт ФГБУ «НМХЦ им. Н.И. Пирогова» Минздрава РоссииHigh-dose chemotherapy following autologous hematopoietic stem cell transplantation for Hodgkin lymphoma. 10 years’ experience of the N.I. Pirogov National Medical and Surgical Center Ministry of Health of RussiaМочкинН. Е.MochkinN. E.

105043, Москва, ул. Нижняя Первомайская, 70

70 Nizhnyaya Pervomayskaya St., Moscow, 105043

nickmed@yandex.ruСаржевскийВ. О.SarzhevskiyV. O.

105043, Москва, ул. Нижняя Первомайская, 70

70 Nizhnyaya Pervomayskaya St., Moscow, 105043

ДубининаЮ. Н.DubininaYu. N.

105043, Москва, ул. Нижняя Первомайская, 70

70 Nizhnyaya Pervomayskaya St., Moscow, 105043

СмирноваЕ. Г.SmirnovaE. G.

105043, Москва, ул. Нижняя Первомайская, 70

70 Nizhnyaya Pervomayskaya St., Moscow, 105043

ФедоренкоД. А.FedorenkoD. A.

105043, Москва, ул. Нижняя Первомайская, 70

70 Nizhnyaya Pervomayskaya St., Moscow, 105043

БанниковаА. Е.BannikovaA. E.

105043, Москва, ул. Нижняя Первомайская, 70

70 Nizhnyaya Pervomayskaya St., Moscow, 105043

КолесниковаД. С.KolesnikovaD. S.

105043, Москва, ул. Нижняя Первомайская, 70

70 Nizhnyaya Pervomayskaya St., Moscow, 105043

МельниченкоВ. Я.MelnichenkoV. Ya.

105043, Москва, ул. Нижняя Первомайская, 70

70 Nizhnyaya Pervomayskaya St., Moscow, 105043

ФГБУ «Национальный медико-хирургический центр им. Н.И. Пирогова» Минздрава РоссииРоссияN.I. Pirogov National Medical and Surgical Center Ministry of Health of RussiaRussian Federation201716062017428590Copyright © Мочкин Н.Е., Саржевский В.О., Дубинина Ю.Н., Смирнова Е.Г., Федоренко Д.А., Банникова А.Е., Колесникова Д.С., Мельниченко В.Я., 20172017Мочкин Н.Е., Саржевский В.О., Дубинина Ю.Н., Смирнова Е.Г., Федоренко Д.А., Банникова А.Е., Колесникова Д.С., Мельниченко В.Я.Mochkin N.E., Sarzhevskiy V.O., Dubinina Y.N., Smirnova E.G., Fedorenko D.A., Bannikova A.E., Kolesnikova D.S., Melnichenko V.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nodgo.org/jour/article/view/298

В статье представлен современный взгляд на место и значение аутологичной трансплантации кроветворных стволовых клеток в лечении лимфомы Ходжкина, а также 10-летние результаты использования аутологичной трансплантации в ФГБУ «НМХЦ им. Н.И. Пирогова» Минздрава России. Пятилетняя общая выживаемость составила 63 %, 5-летняя безрецидивная выживаемость – 84 %, что соответствует данным ряда международных исследований. Было показано, что достижение полного ответа является основным прогностическим фактором эффективности высокодозной химиотерапии с аутологичной трансплантацией кроветворных стволовых клеток.

The article represents the role of high-dose chemotherapy following autologous hematopoietic stem cell transplantation for Hodgkin lymphoma and summarizes the results of 10-years’ experience of high-dose chemotherapy following autologous hematopoietic stem transplantation cell for Hodgkin lymphoma in N.I. Pirogov National Medical and Surgical Center. 5-year overall survival was 63 %, 5-year progressivefree survival – 84 % that corresponds with international data. Complete response before high-dose chemotherapy following autologous hematopoietic stem cell was the main independent prognostic factor of transplantation efficacy. transplantation.

лимфома Ходжкинавысокодозная химиотерапиятрансплантация аутологичных кроветворных стволовых клетокHodgkin lymphomahigh-dose chemotherapyautologous hematopoietic stem cell transplantationReferencesАбдурахманов Д.Т., Абузарова Г.Р., Аль-Ради Л.С. и др. Российские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний. Под ред. проф. И.В. Поддубной и проф. В.Г. Савченко. М.: Типография ООО «Буки Веди», 2016. 324 с. [Abdurakhmanov D.T., Abuzarova G.R., Al-Radi L.S. et al. Russian clinical guidelines for the diagnosis and treatment of lymphoproliferative diseases. Edited by prof. I.V. Poddubnya and prof. V.G. Savchenko. M .: Tipografiya Buki Vedi, 2016. 324 p. (In Russ.)].Абдурахманов Д.Т., Абузарова Г.Р., Аль-Ради Л.С. и др. Российские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний. Под ред. проф. И.В. Поддубной и проф. В.Г. Савченко. М.: Типография ООО «Буки Веди», 2016. 324 с. [Abdurakhmanov D.T., Abuzarova G.R., Al-Radi L.S. et al. Russian clinical guidelines for the diagnosis and treatment of lymphoproliferative diseases. Edited by prof. I.V. Poddubnya and prof. V.G. Savchenko. M .: Tipografiya Buki Vedi, 2016. 324 p. (In Russ.)].Skoetz N., Trelle S., Rancea M. et al. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin’s lymphoma: a systematic review and network meta-analysis. Lancet Oncol 2013:14(10):943–52.Skoetz N., Trelle S., Rancea M. et al. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin’s lymphoma: a systematic review and network meta-analysis. Lancet Oncol 2013:14(10):943–52.Kuruvilla J., Keating A., Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood 2011;117(16):4208–17.Kuruvilla J., Keating A., Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood 2011;117(16):4208–17.Thomas R.K., Re D., Zander T. et al. Epidemiology and etiology of Hodgkin’s lymphoma. Ann Oncol 2002;13(Supl.4):147–52.Thomas R.K., Re D., Zander T. et al. Epidemiology and etiology of Hodgkin’s lymphoma. Ann Oncol 2002;13(Supl.4):147–52.Linch D., Winfield D., Goldstone A. et al. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin disease: results of a BNLI randomized trial. Lancet 1993;341:1051–4.Linch D., Winfield D., Goldstone A. et al. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin disease: results of a BNLI randomized trial. Lancet 1993;341:1051–4.Schmitz N., Pfistner B., Sextro M. et al. Aggressive conventional chemotherapy compaired with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin disease: a randomized trial. Lancet 2002;359(9323):2065–71.Schmitz N., Pfistner B., Sextro M. et al. Aggressive conventional chemotherapy compaired with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin disease: a randomized trial. Lancet 2002;359(9323):2065–71.Josting A., Franklin J., May M. et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin’s lymphoma registered in the database of the German Hodgkin’s lymphoma study group. J Clin Oncol 2002;20(1):221–30.Josting A., Franklin J., May M. et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin’s lymphoma registered in the database of the German Hodgkin’s lymphoma study group. J Clin Oncol 2002;20(1):221–30.Ljungman P., Bregni M., Brune M. et al. Allogenic and autologous transplantation for haematologocal disease, solid tumors and immune disorders: current practice in Europe 2009. Bone Marrow Transplant 2010;45:219–34.Ljungman P., Bregni M., Brune M. et al. Allogenic and autologous transplantation for haematologocal disease, solid tumors and immune disorders: current practice in Europe 2009. Bone Marrow Transplant 2010;45:219–34.Perales M.A., Ceberio I., Armand P. et al. Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2015;21(6):971–83.Perales M.A., Ceberio I., Armand P. et al. Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2015;21(6):971–83.NCCN Guidelines for Hodgkin Lymphoma. Version 1.2017.NCCN Guidelines for Hodgkin Lymphoma. Version 1.2017.Moscowitz C.H., Kewalramani T., Nimer S.D. et al. Effectivness of high-dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin’s disease. Br J Haematol 2004;124:645–52.Moscowitz C.H., Kewalramani T., Nimer S.D. et al. Effectivness of high-dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin’s disease. Br J Haematol 2004;124:645–52.Sirohi B., Cunningham D., Powles R. et al. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma. Ann Oncol 2008;19:1312–9.Sirohi B., Cunningham D., Powles R. et al. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma. Ann Oncol 2008;19:1312–9.Provencio M., Sánchez A., Sánchez-Beato M. New drugs and targeted treatments in Hodgkin’s lymphoma. Cancer Treat Rev 2014;40(3):457–64.Provencio M., Sánchez A., Sánchez-Beato M. New drugs and targeted treatments in Hodgkin’s lymphoma. Cancer Treat Rev 2014;40(3):457–64.Gopal A.K., Chen R., Smith S.E. et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood 2015;125(8):1236–43.Gopal A.K., Chen R., Smith S.E. et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood 2015;125(8):1236–43.Armand P., Shipp M.A., Ribrag V. et al. Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. J Clin Oncol 2016. pii: JCO673467. [Epub ahead of print].Armand P., Shipp M.A., Ribrag V. et al. Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. J Clin Oncol 2016. pii: JCO673467. [Epub ahead of print].Younes A., Santoro A., Shipp M. et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 2016;17(9):1283–94.Younes A., Santoro A., Shipp M. et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 2016;17(9):1283–94.Moskowitz C.H., Nimer S.D., Zelenets A.D. et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001;97:616–23.Moskowitz C.H., Nimer S.D., Zelenets A.D. et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001;97:616–23.Phillips J.K., Spearing R.L., Davies J.M. et al. VIM-D salvage chemotherapy in Hodgkin’s disease. Cancer Chemother Pharmacol 1990;27:161–3.Phillips J.K., Spearing R.L., Davies J.M. et al. VIM-D salvage chemotherapy in Hodgkin’s disease. Cancer Chemother Pharmacol 1990;27:161–3.ChlVPP therapy for Hodgkin’s disease: experience of 960 patients. The International ChlVPP Treatment Group. Ann Oncol 1995;6:167–72.ChlVPP therapy for Hodgkin’s disease: experience of 960 patients. The International ChlVPP Treatment Group. Ann Oncol 1995;6:167–72.Colwill R., Crump M., Couture F. et al. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin’s disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol 1995;13:396–402.Colwill R., Crump M., Couture F. et al. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin’s disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol 1995;13:396–402.Rodriguez M.A., Cabanillas F.C., Hagemeister F.B. et al. A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas. Ann Oncol 1995;6:609–11.Rodriguez M.A., Cabanillas F.C., Hagemeister F.B. et al. A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas. Ann Oncol 1995;6:609–11.Aparicio J., Segura A., Garcera S. et al. ESHAP is an active regimen for relapsing Hodgkin’s disease. Ann Oncol 1999;10:593–5.Aparicio J., Segura A., Garcera S. et al. ESHAP is an active regimen for relapsing Hodgkin’s disease. Ann Oncol 1999;10:593–5.Martin A., Femandez-Jimenez M.C., Caballero M.D. et al. Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin’s disease. Br J Haematol 2001;113:161–71.Martin A., Femandez-Jimenez M.C., Caballero M.D. et al. Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin’s disease. Br J Haematol 2001;113:161–71.Josting A., Rudolph C., Reiser M. et al. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin’s disease. Ann Oncol 2002;13:1628–35.Josting A., Rudolph C., Reiser M. et al. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin’s disease. Ann Oncol 2002;13:1628–35.Abali H., Urün Y., Oksüzoğlu B. et al. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. Cancer Invest 2008;26(4):401–6.Abali H., Urün Y., Oksüzoğlu B. et al. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. Cancer Invest 2008;26(4):401–6.European Society for Blood and Marrow Transplantation Annual Report, 2016.European Society for Blood and Marrow Transplantation Annual Report, 2016.Passweg J.R., Baldomero H., Bregni M. et al. Hematopoietic SCT in Europe: data and trends in 2011. Bone Marrow Transplant 2013;48:1161–7.Passweg J.R., Baldomero H., Bregni M. et al. Hematopoietic SCT in Europe: data and trends in 2011. Bone Marrow Transplant 2013;48:1161–7.Жуков Н.В., Усс А.Л., Миланович Н.Ф. и др. Оптимальные сроки проведения аутологичной трансплантации клеток предшественников гемопоэза при неблагоприятном течении лимфомы Ходжкина. Зарубежные рекомендации и отечественная практика. Онкогематология 2014;9(2):37–44. [Zhukov N.V., Uss A.L., Milanovich N.F. et al. The optimal time for autologous hematopoietic progenitor cell transplantation during treatment of Hodgkin’s lymphoma. Foreign recommendations and russian experience. Onkogematologiya = Oncohematology 2014;9(2):37–44. (In Russ.)].Жуков Н.В., Усс А.Л., Миланович Н.Ф. и др. Оптимальные сроки проведения аутологичной трансплантации клеток предшественников гемопоэза при неблагоприятном течении лимфомы Ходжкина. Зарубежные рекомендации и отечественная практика. Онкогематология 2014;9(2):37–44. [Zhukov N.V., Uss A.L., Milanovich N.F. et al. The optimal time for autologous hematopoietic progenitor cell transplantation during treatment of Hodgkin’s lymphoma. Foreign recommendations and russian experience. Onkogematologiya = Oncohematology 2014;9(2):37–44. (In Russ.)].Moskowitz A.J., Hamlin P.A., Perales M.A. et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol 2013;31(4):456–60.Moskowitz A.J., Hamlin P.A., Perales M.A. et al. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol 2013;31(4):456–60.Visani G., Malerba L., Stefani P.M. et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood 2011;118(12):3419–25.Visani G., Malerba L., Stefani P.M. et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood 2011;118(12):3419–25.

The authors declare that there are no conflicts of interest present.